Roche, FDA announce new drug-interaction warnings for mibefradil.
D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D000075202:Contraindications; D016572:Cyclosporine / Q000008:administration & dosage; D004347:Drug Interactions; D004348:Drug Labeling; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D020748:Mibefradil; D016559:Tacrolimus / Q000008:administration & dosage; D013764:Tetrahydronaphthalenes; D014481:United States; D014486:United States Food and Drug Administration
D000924:Anticholesteremic Agents; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D016572:Cyclosporine; D016559:Tacrolimus